🇺🇸 FDA

Intelligence Platform

Patents

Browse 36 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11078295

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tum

VACCINEX, INC. · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800853

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to i

VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10494440

Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

VACCINEX, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10385136

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9828435

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4

VACCINEX, INC. · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9598495

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Mar 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512224

Use of semaphorin-4D binding molecules for treatment of atherosclerosis

VACCINEX, INC. · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9249227

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

VACCINEX, INC. · Granted Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9243068

Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

VACCINEX, INC. · Granted Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8790652

Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules

VACCINEX, INC. · Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7919246

SEMA4D in cancer diagnosis, detection and treatment

Sagres Discovery, Inc. · Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted